-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Since April, many pharmaceutical companies have achieved IPOs
.
On April 21, the results of the 21st review meeting of the GEM Listing Committee in 2022 were announced, and Shanghai Hongbo Zhiyuan Pharmaceutical Co.
, Ltd.
(referred to as "Hongbo Pharmaceutical") was approved for the first time
.
CITIC Securities, as its sponsor, plans to raise 477.
07 million yuan, and the number of raised investment projects is 2, which are for the construction of pre-clinical new drug research and development bases and to supplement working capital
.
According to the prospectus, Hongbo Pharmaceutical is a one-stop comprehensive service provider for new drug research and development and commercial production, dedicated to drug discovery, research and development of pharmaceutical processes, and commercial production of API intermediates
.
Based on the key links in the new drug research and development industry chain, the company builds a comprehensive technical service platform covering drug discovery, process research and development, as well as a commercial production platform for the production of new drug key intermediates and independent products
.
On April 15, the 29th review meeting of the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee in 2022 was held.
The review results showed that Shanghai United Imaging Medical Technology Co.
, Ltd.
(referred to as "United Imaging Medical") met the issuance conditions, listing conditions and Information Disclosure Requirements
.
According to the data, United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions
.
United Imaging Medical plans to list on the Shanghai Stock Exchange’s Science and Technology Innovation Board this time, and plans to publicly issue no more than 100 million shares (before the over-allotment option is exercised); no more than 115 million shares (after the over-allotment option is exercised in full)
.
This offering does not involve a public offering of shares by shareholders
.
United Imaging Medical plans to raise funds of 12.
48 billion yuan, which will be used for next-generation product research and development projects, high-end medical imaging equipment industrialization fund projects, marketing service network projects, informatization improvement projects, and supplementary working capital
.
On April 12, 2022, the Shanghai Stock Exchange disclosed that the 27th review meeting of the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee in 2022 was held on the morning of April 12, 2022.
Nuocheng Jianhua Pharmaceutical Co.
, Ltd.
(first issue): meet the issuance conditions, Listing conditions and disclosure requirements
.
Nuocheng Jianhua plans to raise 4 billion yuan this time, of which 2.
15 billion yuan will be used for new drug research and development projects; 167 million yuan will be used for drug research and development platform upgrade projects; 394 million yuan will be used for marketing network construction projects; 87.
7385 million yuan will be used for Informatization construction projects; 1.
2 billion yuan is used to supplement working capital
.
In addition, recently, the 20th review meeting of the GEM Listing Committee in 2022 was held.
The review results showed that the IPO of Shenzhen Meichuangyi Medical Technology Co.
, Ltd.
(“Meihao Medical”) met the issuance conditions, listing conditions and information disclosure requirements.
.
According to the data, Good Medical focuses on the design, development, manufacture and sales of precision components and products for medical devices
.
Based on the development technology of medical device components and products, plastic and liquid silicone precision molds and molding technology, automation technology, precision manufacturing technology and a sound medical device compliance management system, the company provides domestic and foreign medical device customers with product design and development.
Full-process service from mass production delivery
.
Good Medical plans to be listed on the GEM of Shenzhen Stock Exchange this time, the number of issued shares is not less than 44.
27 million shares, and the number of issued shares accounts for not less than 10% of the company's total share capital after the issuance; all new shares are publicly issued, and the company's shareholders will not make public On sale
.
The company plans to raise 1 billion yuan for the R&D and production projects of Michuangyi's key equipment for the diagnosis and treatment of respiratory diseases and a cloud platform for respiratory health big data management
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
On April 21, the results of the 21st review meeting of the GEM Listing Committee in 2022 were announced, and Shanghai Hongbo Zhiyuan Pharmaceutical Co.
, Ltd.
(referred to as "Hongbo Pharmaceutical") was approved for the first time
.
CITIC Securities, as its sponsor, plans to raise 477.
07 million yuan, and the number of raised investment projects is 2, which are for the construction of pre-clinical new drug research and development bases and to supplement working capital
.
According to the prospectus, Hongbo Pharmaceutical is a one-stop comprehensive service provider for new drug research and development and commercial production, dedicated to drug discovery, research and development of pharmaceutical processes, and commercial production of API intermediates
.
Based on the key links in the new drug research and development industry chain, the company builds a comprehensive technical service platform covering drug discovery, process research and development, as well as a commercial production platform for the production of new drug key intermediates and independent products
.
On April 15, the 29th review meeting of the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee in 2022 was held.
The review results showed that Shanghai United Imaging Medical Technology Co.
, Ltd.
(referred to as "United Imaging Medical") met the issuance conditions, listing conditions and Information Disclosure Requirements
.
According to the data, United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions
.
United Imaging Medical plans to list on the Shanghai Stock Exchange’s Science and Technology Innovation Board this time, and plans to publicly issue no more than 100 million shares (before the over-allotment option is exercised); no more than 115 million shares (after the over-allotment option is exercised in full)
.
This offering does not involve a public offering of shares by shareholders
.
United Imaging Medical plans to raise funds of 12.
48 billion yuan, which will be used for next-generation product research and development projects, high-end medical imaging equipment industrialization fund projects, marketing service network projects, informatization improvement projects, and supplementary working capital
.
On April 12, 2022, the Shanghai Stock Exchange disclosed that the 27th review meeting of the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee in 2022 was held on the morning of April 12, 2022.
Nuocheng Jianhua Pharmaceutical Co.
, Ltd.
(first issue): meet the issuance conditions, Listing conditions and disclosure requirements
.
Nuocheng Jianhua plans to raise 4 billion yuan this time, of which 2.
15 billion yuan will be used for new drug research and development projects; 167 million yuan will be used for drug research and development platform upgrade projects; 394 million yuan will be used for marketing network construction projects; 87.
7385 million yuan will be used for Informatization construction projects; 1.
2 billion yuan is used to supplement working capital
.
In addition, recently, the 20th review meeting of the GEM Listing Committee in 2022 was held.
The review results showed that the IPO of Shenzhen Meichuangyi Medical Technology Co.
, Ltd.
(“Meihao Medical”) met the issuance conditions, listing conditions and information disclosure requirements.
.
According to the data, Good Medical focuses on the design, development, manufacture and sales of precision components and products for medical devices
.
Based on the development technology of medical device components and products, plastic and liquid silicone precision molds and molding technology, automation technology, precision manufacturing technology and a sound medical device compliance management system, the company provides domestic and foreign medical device customers with product design and development.
Full-process service from mass production delivery
.
Good Medical plans to be listed on the GEM of Shenzhen Stock Exchange this time, the number of issued shares is not less than 44.
27 million shares, and the number of issued shares accounts for not less than 10% of the company's total share capital after the issuance; all new shares are publicly issued, and the company's shareholders will not make public On sale
.
The company plans to raise 1 billion yuan for the R&D and production projects of Michuangyi's key equipment for the diagnosis and treatment of respiratory diseases and a cloud platform for respiratory health big data management
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
